Alzheimer Disease Clinical Trials in Walnut Creek, California

5 studies are recruiting for alzheimer disease in Walnut Creek, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

   The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1651, Walnut Creek, California

   Locations

   252 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06937229 on ClinicalTrials.gov

2. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Sunwise Clinical Research, Walnut Creek, California

   Locations

   162 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011732 on ClinicalTrials.gov

3. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

   This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

   Stage

   Phase 2

   Ages

   55 and older

   Site

   Sunwise Clinical Research, Walnut Creek, California

   Locations

   67 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06540833 on ClinicalTrials.gov

4. Senicapoc in Alzheimer's Disease

   Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity …

   Stage

   Phase 2

   Ages

   55 to 85

   Site

   UC Davis Alzheimer's Disease Center East Bay, Walnut Creek, California

   Locations

   2 in total

   Run by

   University of California, Davis

   See if you can join NCT04804241 on ClinicalTrials.gov

5. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Infectious Disease Doctors Medical Group, APC, Walnut Creek, California

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov